Medical School · Year 3 · Family Medicine · includes a quiz and discussion video

Seminar 02: Preventive Care and Health Maintenance

Year 3: Family Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Apply age-appropriate screening recommendations
2. Implement vaccination schedules for all ages
3. Counsel patients on health behaviors
4. Calculate cardiovascular risk and apply prevention strategies
5. Perform cancer screening per guidelines
6. Document and track preventive services

Seminar Outline

I. Principles of Screening

Effective screening programs must satisfy rigorous criteria that distinguish beneficial early detection from wasteful or harmful testing of asymptomatic populations. The target condition must represent an important health problem with significant morbidity or mortality, justifying the resources and potential harms involved in population-wide screening. A detectable preclinical phase must exist during which the disease can be identified before symptoms develop, and the screening test must be capable of reliably detecting disease during this window. Available treatment must offer improved outcomes when disease is detected early compared to waiting for symptomatic presentation, establishing that early detection provides meaningful benefit rather than merely advancing diagnosis without changing prognosis. The screening test itself must be safe, acceptable to patients, and the healthcare system must have capacity to manage individuals who screen positive.

The United States Preventive Services Task Force provides evidence-based grading of screening recommendations that guides clinical practice. Grade A recommendations indicate high certainty that net benefit is substantial, warranting routine implementation for eligible populations. Grade B recommendations reflect high certainty of moderate benefit or moderate certainty of substantial benefit, also warranting routine implementation. Grade C recommendations indicate that evidence supports selective offering based on individual circumstances, with benefits and harms closely balanced such that patient preferences should drive decisions. Grade D recommendations advise against screening due to absent benefit or harms exceeding benefits. Grade I indicates insufficient evidence to assess balance of benefits and harms, requiring clinical judgment without guideline support. Understanding these grades enables appropriate application of recommendations and identification of situations requiring shared decision-making.

Screening test characteristics determine performance in distinguishing individuals with and without disease. Sensitivity measures the proportion of true positives among all individuals with disease, reflecting the test's ability to detect disease when present. Specificity measures the proportion of true negatives among all individuals without disease, reflecting the test's ability to correctly classify healthy individuals. Positive predictive value indicates the probability that a positive test reflects true disease, heavily influenced by disease prevalence in the screened population. Negative predictive value indicates the probability that a negative test reflects true absence of disease. The number needed to screen calculates how many individuals must undergo screening to prevent one adverse outcome, providing practical perspective on screening efficiency. These characteristics inform interpretation of individual results and comparison among alternative screening strategies.

Screening programs inevitably produce harms that must be balanced against benefits when evaluating overall value. False positive results generate anxiety, require confirmatory testing that may itself carry risks, and potentially lead to unnecessary procedures with their own complications. Overdiagnosis identifies conditions that would never have caused symptoms or death during the patient's lifetime, subjecting individuals to treatment burdens without corresponding benefit. False negative results provide inappropriate reassurance that may delay recognition of symptomatic disease or reduce vigilance for warning signs. Direct harms from screening procedures themselves include radiation exposure from imaging, bleeding from biopsies, and procedural complications. Recognizing these harms enables informed conversations with patients about screening tradeoffs and identifies opportunities to minimize harm through appropriate test selection and follow-up protocols.

<image>Panel A: Flowchart depicting the criteria for effective screening programs including important condition, detectable preclinical phase, effective treatment, and acceptable test with decision points for program implementation. Panel B: USPSTF grading scale showing grades A through I with definitions and clinical implications for each recommendation level. Panel C: Two-by-two table illustrating sensitivity, specificity, positive predictive value, and negative predictive value calculations with example numbers. Panel D: Diagram showing screening harms including false positives, overdiagnosis, false negatives, and direct procedure risks with relative frequency indicators.</image>

II. Cancer Screening

Breast cancer screening through mammography represents one of the most discussed and debated preventive services, with guidelines varying across organizations. The USPSTF recommends biennial screening mammography for women ages fifty through seventy-four as a Grade B recommendation, while recommending individualized decision-making for women ages forty through forty-nine as Grade C, recognizing that younger women experience lower disease prevalence and higher false positive rates. The American Cancer Society recommends annual mammography beginning at age forty-five with transition to biennial screening at age fifty-five. High-risk women including those with strong family history, genetic mutations, or prior chest radiation may benefit from earlier initiation and addition of breast MRI to mammography. Shared decision-making should address the modest mortality reduction achieved through screening against the substantial false positive rates, recall examinations, and potential overdiagnosis of indolent cancers.

Cervical cancer screening has evolved substantially with recognition of human papillomavirus as the necessary cause and development of HPV-based testing strategies. Women under age twenty-one require no screening regardless of sexual activity, as cervical cancer is rare and abnormalities typically resolve spontaneously. Women ages twenty-one through twenty-nine should receive Pap smear alone every three years, as HPV testing in this age group would detect transient infections with high spontaneous clearance rates. Women ages thirty through sixty-five have multiple acceptable options including Pap smear every three years, co-testing with Pap and HPV every five years, or primary HPV testing every five years. Screening may cease after age sixty-five for women with adequate prior screening showing no significant abnormalities. Women who have undergone hysterectomy with removal of the cervix for benign indications require no further screening.

Colorectal cancer screening should begin at age forty-five for average-risk individuals and continue through age seventy-five, with individualized decisions for ages seventy-six through eighty-five and cessation beyond eighty-five. Multiple screening modalities offer comparable effectiveness, allowing patient preference to guide selection. Colonoscopy every ten years provides direct visualization with opportunity for polypectomy but requires bowel preparation and carries procedure risks. Annual fecal immunochemical testing offers non-invasive option that detects hemoglobin in stool but requires colonoscopy for positive results and annual repetition. Stool DNA testing with fecal immunochemical testing every one to three years provides enhanced sensitivity but with increased false positive rates and cost. Flexible sigmoidoscopy every five years combined with interval FIT examines the distal colon where most cancers arise while reducing procedure burden compared to colonoscopy.

Lung cancer screening with low-dose computed tomography annually represents the most recently established cancer screening recommendation, targeting the population at highest risk. Eligibility criteria include age fifty through eighty years, smoking history of at least twenty pack-years, and either current smoking or cessation within the past fifteen years. The USPSTF Grade B recommendation reflects evidence of mortality reduction in the National Lung Screening Trial, though benefits must be weighed against substantial false positive rates, radiation exposure, and potential complications from diagnostic procedures following positive screens. Shared decision-making is required, ensuring patients understand benefits, limitations, and potential harms. Screening should discontinue when individuals have not smoked for fifteen years or develop health problems that would preclude curative treatment or substantially limit life expectancy. Prostate cancer screening remains controversial, with the USPSTF recommending shared decision-making for men ages fifty-five through sixty-nine and recommending against screening for men seventy and older, reflecting the balance between potential mortality reduction and substantial risks of overdiagnosis and overtreatment.

<image>Panel A: Breast cancer screening timeline showing age-based recommendations from USPSTF and ACS with mammography intervals and consideration of risk factors for enhanced screening. Panel B: Cervical cancer screening algorithm showing age-stratified approaches from under twenty-one through post-sixty-five including Pap, co-testing, and HPV primary screening options. Panel C: Colorectal cancer screening options comparison showing colonoscopy, FIT, stool DNA, and sigmoidoscopy with intervals, preparation requirements, and key considerations. Panel D: Lung cancer screening eligibility criteria flowchart showing age, pack-year, and cessation history requirements with shared decision-making process.</image>

III. Cardiovascular Disease Prevention

Cardiovascular risk assessment provides foundation for prevention decisions including statin therapy initiation and blood pressure treatment intensity. The pooled cohort equations estimate ten-year risk of atherosclerotic cardiovascular disease events including myocardial infarction and stroke based on age, sex, race, total and HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes, and smoking status. Risk categories stratify individuals as low risk below five percent, borderline risk from five to seven and a half percent, intermediate risk from seven and a half to twenty percent, and high risk above twenty percent. This risk stratification guides treatment intensity, with higher-risk individuals deriving greater absolute benefit from interventions and therefore warranting more aggressive management. Risk calculators are widely available as online tools and mobile applications, enabling routine incorporation into clinical practice.

Statin therapy recommendations depend upon clinical atherosclerotic cardiovascular disease status, LDL cholesterol level, diabetes status, and calculated ten-year risk. Individuals with established clinical ASCVD including prior myocardial infarction, stroke, or peripheral arterial disease should receive high-intensity statin therapy regardless of calculated risk, as secondary prevention provides substantial benefit. Those with LDL cholesterol one hundred ninety or above warrant high-intensity statin therapy due to markedly elevated lifetime cardiovascular risk. Adults ages forty through seventy-five with diabetes should receive at least moderate-intensity statin therapy, with high-intensity therapy appropriate when additional risk factors are present. For primary prevention in individuals without diabetes, those with ten-year risk exceeding twenty percent should receive high-intensity statin therapy, while those with intermediate risk should engage in shared decision-making considering additional risk-enhancing factors such as family history, metabolic syndrome, chronic kidney disease, or elevated inflammatory markers.

Hypertension management contributes substantially to cardiovascular risk reduction, with current guidelines defining elevated blood pressure at lower thresholds than historical standards. Normal blood pressure is below one hundred twenty systolic and below eighty diastolic. Elevated blood pressure includes systolic readings from one hundred twenty through one hundred twenty-nine with diastolic below eighty, warranting lifestyle modification. Stage one hypertension encompasses systolic one hundred thirty through one hundred thirty-nine or diastolic eighty through eighty-nine, with pharmacotherapy recommended when ten-year ASCVD risk exceeds ten percent or when cardiovascular disease, diabetes, or chronic kidney disease is present. Stage two hypertension includes systolic one hundred forty or above or diastolic ninety or above, warranting pharmacotherapy in addition to lifestyle modification for all affected individuals. Blood pressure targets of below one hundred thirty over eighty apply to most patients, though individualization remains appropriate for elderly patients in whom aggressive control may produce adverse effects.

Aspirin for primary cardiovascular prevention has undergone substantial revision based on recent trial evidence demonstrating that bleeding risks largely offset cardiovascular benefits in contemporary populations receiving improved management of underlying risk factors. The USPSTF now recommends against routine aspirin use for primary prevention in most individuals, representing a significant change from prior guidance. For individuals ages forty through seventy with elevated cardiovascular risk and low bleeding risk, aspirin may be considered through shared decision-making that carefully weighs modest cardiovascular benefit against meaningful bleeding risk. Aspirin is not recommended for primary prevention in individuals over age seventy or those with increased bleeding risk. Secondary prevention with aspirin remains clearly indicated for individuals with established cardiovascular disease, where benefits substantially exceed risks.

<image>Panel A: ASCVD risk calculator interface showing input variables including age, sex, race, cholesterol values, blood pressure, diabetes, and smoking with output displaying ten-year risk percentage and risk category. Panel B: Statin therapy decision algorithm showing pathways for clinical ASCVD, LDL greater than 190, diabetes, and risk-based primary prevention with recommended intensities. Panel C: Blood pressure classification diagram showing normal, elevated, stage one, and stage two categories with corresponding systolic and diastolic ranges and management approaches. Panel D: Aspirin primary prevention decision framework showing risk-benefit balance for different age groups and clinical scenarios with current recommendations.</image>

IV. Immunizations

Adult immunization schedules maintain protection against vaccine-preventable diseases throughout the lifespan, with several vaccines warranting annual or periodic administration. Influenza vaccination is recommended annually for all adults, with high-dose formulations preferred for those age sixty-five and older due to enhanced immunogenicity in this population with diminished immune response to standard doses. Tetanus, diphtheria, and pertussis protection requires one dose of Tdap for all adults who have not previously received it, followed by Td boosters every ten years. COVID-19 vaccination follows evolving recommendations that adapt to viral variants and population immunity, with updated boosters recommended as available. Shingrix recombinant zoster vaccine is recommended as two doses for adults age fifty and older, providing substantially improved protection compared to the prior live vaccine. Pneumococcal vaccination for adults age sixty-five and older now recommends either PCV15 followed by PPSV23 or PCV20 alone, with specific algorithms for those with prior vaccination.

Catch-up vaccination addresses gaps in immunization that may result from incomplete childhood series, immigration from regions with different schedules, or waning immunity requiring booster doses. Measles, mumps, and rubella vaccination should be ensured for adults born after 1957 who lack documentation of vaccination or immunity, particularly those in healthcare settings, educational institutions, or with international travel plans. Varicella vaccination is recommended for adults without evidence of immunity including history of disease, vaccination, or laboratory confirmation of protection. Human papillomavirus vaccination is recommended through age twenty-six with catch-up vaccination, and shared decision-making may support vaccination through age forty-five for those not previously vaccinated. Hepatitis A vaccination is recommended for adults at increased risk including travelers to endemic regions, individuals with chronic liver disease, and men who have sex with men.

Special populations require modified vaccination approaches that account for immunocompromise, pregnancy, or occupational exposures. Pregnant women should receive influenza vaccine during any trimester and Tdap vaccine during each pregnancy, preferably during the early third trimester to maximize antibody transfer to the newborn. Live vaccines including MMR and varicella are contraindicated during pregnancy but should be administered postpartum if immunity is lacking. Immunocompromised individuals should generally avoid live vaccines but may require additional doses of inactivated vaccines to achieve protection. Healthcare workers require documentation of immunity to measles, mumps, rubella, varicella, and hepatitis B, with influenza vaccination often mandated by institutional policy. Travelers should receive region-specific vaccines that may include yellow fever, typhoid, hepatitis A, and meningococcal vaccines depending on destination.

Vaccine hesitancy has emerged as a significant barrier to achieving population immunity and requires thoughtful communication approaches. Listening to parental or patient concerns with genuine curiosity and without judgment establishes rapport and identifies specific concerns that can be addressed. Providing accurate information that directly responds to stated concerns proves more effective than generic vaccine promotion. Strong physician recommendations substantially influence vaccination decisions, as patients often trust their physician's guidance over other information sources. Acknowledging that vaccines, like all medical interventions, carry small risks while emphasizing the substantially larger risks of vaccine-preventable diseases helps calibrate risk perception. When patients decline vaccination, documenting the discussion and offering vaccination at subsequent visits maintains the relationship while preserving opportunity for future acceptance.

<image>Panel A: Adult immunization schedule grid showing recommended vaccines by age group from nineteen through sixty-five plus including influenza, Tdap, zoster, pneumococcal, and hepatitis B with timing intervals. Panel B: Catch-up vaccination decision tree for adults lacking documentation of MMR, varicella, HPV, and hepatitis immunity with criteria and dosing schedules. Panel C: Special population vaccination considerations showing modifications for pregnancy, immunocompromise, healthcare workers, and travelers with contraindicated and recommended vaccines. Panel D: Vaccine hesitancy communication framework illustrating listen, acknowledge, provide information, recommend, and follow-up approach with example phrases.</image>

V. Lifestyle Counseling

Diet and nutrition counseling addresses modifiable risk factors for cardiovascular disease, diabetes, and cancer that rank among the leading causes of morbidity and mortality. Evidence supports dietary patterns emphasizing fruits and vegetables with goal of five or more servings daily, whole grains comprising the majority of grain consumption, lean protein sources including fish, poultry, and legumes, and limitation of processed foods, added sugars, saturated fat, and sodium. The USPSTF recommends intensive behavioral counseling for adults with cardiovascular risk factors as a Grade B recommendation, recognizing that brief office-based counseling alone produces modest effects while more intensive interventions demonstrate meaningful impact. Referral to registered dietitians, enrollment in structured programs, and provision of educational materials extend counseling beyond what time-limited office visits can accomplish.

Physical activity recommendations specify minimum thresholds for health benefit while encouraging additional activity for enhanced outcomes. Adults should accumulate at least one hundred fifty minutes of moderate-intensity aerobic activity or seventy-five minutes of vigorous-intensity activity weekly, distributed across multiple days. Muscle-strengthening activities targeting major muscle groups should occur at least two days weekly. Older adults should additionally incorporate balance exercises to reduce fall risk. Benefits extend across virtually all chronic conditions including cardiovascular disease, diabetes, cancer, depression, and dementia, while improving functional capacity and quality of life. Brief counseling to increase physical activity produces small but meaningful effects, with more intensive interventions and referral to structured programs enhancing outcomes. Even brief bouts of activity provide benefit, countering the perception that exercise requires substantial time blocks.

Tobacco cessation represents the single most impactful preventive intervention for smokers, warranting systematic assessment and intervention at every clinical encounter. The five As framework provides structure for tobacco counseling, beginning with asking about tobacco use at every visit to identify users. Advising all tobacco users to quit in clear, personalized language establishes the clinician recommendation. Assessing readiness to quit identifies individuals prepared for cessation support versus those requiring motivational approaches. Assisting through provision of behavioral counseling and pharmacotherapy substantially increases quit rates above unaided attempts. Arranging follow-up maintains support and enables adjustment of strategies for those experiencing difficulty. First-line pharmacotherapies include nicotine replacement therapy in various formulations, bupropion, and varenicline, with combination approaches often more effective than single agents.

Alcohol screening and brief intervention identifies individuals with hazardous use and provides intervention before development of alcohol use disorder. The AUDIT-C provides three-question screening that efficiently identifies at-risk drinking. Single-question screening asking how many times in the past year the patient has had five or more drinks in a day for men or four or more for women also effectively identifies risky use. Recommended limits suggest no more than one drink daily for women and two for men, with lower limits appropriate for older adults and those with relevant medical conditions. Brief intervention for those exceeding recommended limits includes feedback on screening results, recommendation to reduce consumption, collaborative goal-setting, and provision of educational materials. Patients meeting criteria for alcohol use disorder should receive referral to specialty treatment or initiation of medication-assisted treatment with naltrexone or acamprosate.

<image>Panel A: Dietary guidance pyramid emphasizing fruits and vegetables, whole grains, lean proteins, and healthy fats with foods to limit at the apex. Panel B: Physical activity recommendations showing weekly targets for aerobic activity, strength training, and balance exercises with examples of activities in each category. Panel C: Five As tobacco cessation framework showing Ask, Advise, Assess, Assist, and Arrange steps with sample questions and interventions for each. Panel D: Alcohol screening and brief intervention pathway showing AUDIT-C questions, risk stratification, brief intervention components, and referral criteria for alcohol use disorder.</image>

VI. Other Screening Recommendations

Depression screening in primary care is recommended for all adults by the USPSTF as a Grade B recommendation, contingent upon availability of adequate systems to ensure accurate diagnosis and appropriate treatment for those who screen positive. The Patient Health Questionnaire-2 provides efficient initial screening with two questions about depressed mood and anhedonia over the past two weeks. Positive PHQ-2 screens should prompt administration of the full PHQ-9, which assesses all nine DSM criteria for major depression and provides severity scoring. Perinatal depression screening is specifically recommended during pregnancy and the postpartum period, recognizing the particular vulnerability of this period and the impact of maternal depression on infant outcomes. Question nine addressing suicidal ideation requires direct assessment and safety planning when endorsed, regardless of overall screening score.

Diabetes screening identifies individuals with prediabetes who may benefit from intensive lifestyle intervention and those with undiagnosed diabetes requiring treatment. The USPSTF recommends screening for adults ages thirty-five through seventy who are overweight or obese as a Grade B recommendation. Risk factors including family history of diabetes, high-risk ethnicity, history of gestational diabetes, hypertension, and dyslipidemia may warrant earlier screening. Acceptable screening tests include fasting plasma glucose, hemoglobin A1c, or oral glucose tolerance test, with diagnosis requiring confirmation on repeat testing in the absence of unequivocal hyperglycemia. Individuals with prediabetes should receive counseling on intensive lifestyle modification and consideration of metformin for those at highest risk, with annual retesting to monitor for progression.

Osteoporosis screening with dual-energy X-ray absorptiometry is recommended for women age sixty-five and older by the USPSTF as a Grade B recommendation. Postmenopausal women under sixty-five should undergo screening when their fracture risk equals or exceeds that of a sixty-five-year-old white woman without additional risk factors, typically assessed using the FRAX fracture risk assessment tool. Screening intervals are not definitively established but commonly occur every two to four years, with more frequent assessment for those with borderline results or risk factors for rapid bone loss. Men may be considered for screening when clinical risk factors suggest elevated fracture risk, though evidence is less robust for male screening. T-scores below negative two point five indicate osteoporosis warranting treatment, while scores between negative one and negative two point five indicate osteopenia requiring risk assessment and potential treatment.

Infectious disease screening addresses conditions with significant public health implications and available interventions. Hepatitis C virus screening is recommended as one-time testing for all adults ages eighteen through seventy-nine given the availability of curative antiviral therapy and the substantial prevalence of undiagnosed infection. HIV screening should occur at least once for all adults ages fifteen through sixty-five, with more frequent screening for those at increased risk. Syphilis screening is recommended for individuals at increased risk and all pregnant women. Hepatitis B screening targets adults at high risk including those born in high-prevalence regions, injection drug users, and individuals with HIV. Abdominal aortic aneurysm screening with one-time ultrasound is recommended for men ages sixty-five through seventy-five who have ever smoked.

<image>Panel A: Depression screening pathway showing PHQ-2 initial screen, PHQ-9 follow-up for positive screens, and severity-based management approach with score thresholds. Panel B: Diabetes screening algorithm showing eligibility criteria based on age and BMI, acceptable tests, and diagnostic thresholds for prediabetes and diabetes. Panel C: Osteoporosis screening criteria showing age-based recommendations for women, FRAX tool for younger postmenopausal women, and T-score interpretation. Panel D: Infectious disease screening summary showing hepatitis C one-time universal screening, HIV testing recommendations, and targeted screening for syphilis, hepatitis B, and AAA.</image>

VII. Pediatric Prevention

Well-child visits follow a periodicity schedule designed to provide age-appropriate screening, immunization, and anticipatory guidance at critical developmental junctures. Newborn visits address feeding establishment, jaundice monitoring, and completion of metabolic screening. Visits at two weeks, one month, and two months focus on growth assessment, feeding optimization, and parental adjustment. The two, four, and six-month visits combine growth and developmental assessment with critical immunization series initiation. The nine, twelve, fifteen, and eighteen-month visits assess developmental milestones including language emergence and motor progression while completing infant immunization series. Annual well-child visits throughout childhood monitor growth patterns, assess development, update immunizations, and provide age-appropriate anticipatory guidance regarding safety, nutrition, and behavioral expectations.

Developmental screening distinguishes typical variation from delays warranting intervention, enabling early identification and referral that improves outcomes. General developmental screening using validated instruments such as the Ages and Stages Questionnaire should occur at nine, eighteen, and thirty months, with surveillance at every well-child visit. Autism-specific screening with the Modified Checklist for Autism in Toddlers-Revised with Follow-up should occur at eighteen and twenty-four months. Red flags warranting immediate evaluation include absence of babbling by twelve months, absence of gestures such as pointing or waving by twelve months, absence of single words by sixteen months, absence of two-word phrases by twenty-four months, and any loss of previously acquired language or social skills at any age. Failed screening or persistent parental concern despite passed screening warrants referral for comprehensive evaluation regardless of screening results.

Childhood immunization schedules provide protection against serious infectious diseases through systematic vaccination beginning at birth. Hepatitis B vaccine is administered at birth, with completion of the three-dose series by eighteen months. The two, four, and six-month visits provide critical opportunity for DTaP, Hib, pneumococcal, polio, and rotavirus vaccination. The twelve to fifteen-month period introduces MMR, varicella, and hepatitis A vaccination along with completion of several infant series. The four to six-year visit provides booster doses of DTaP, polio, MMR, and varicella. Adolescent vaccination at eleven to twelve years introduces Tdap, meningococcal, and HPV vaccines. Maintaining immunization timeliness protects individual children and contributes to community immunity that shields those who cannot be vaccinated.

Adolescent preventive care addresses the unique health needs and risks of the transition from childhood to adulthood. The HEADSS assessment provides comprehensive psychosocial evaluation covering home environment, education and employment, activities including peer relationships and screen time, drug use, sexuality, and suicide and safety concerns. Confidentiality discussion establishes that most information will remain private while explaining mandatory reporting obligations and encouraging open communication with parents when appropriate. Depression screening using the PHQ-A or similar adolescent-validated instrument should occur annually. Substance use screening using the CRAFFT tool identifies adolescents with hazardous use warranting intervention. Vaccination catch-up addresses any missed childhood vaccines while ensuring completion of the adolescent series including Tdap, MenACWY, and HPV.

<image>Panel A: Well-child visit periodicity schedule showing recommended visit timing from newborn through adolescence with key components at each visit including immunizations, screening, and anticipatory guidance topics. Panel B: Developmental milestone chart showing expected achievements in gross motor, fine motor, language, and social domains from two months through three years with red flags warranting evaluation. Panel C: Childhood immunization schedule showing vaccine timing from birth through eighteen years with critical windows and catch-up opportunities. Panel D: HEADSS adolescent assessment framework showing domains of Home, Education, Activities, Drugs, Sexuality, and Suicide with example questions for each.</image>

VIII. Geriatric Prevention

Preventive care for older adults requires modification of standard recommendations to account for limited life expectancy, competing risks, and individual goals of care. The fundamental principle guiding geriatric prevention recognizes that most screening tests require years for benefits to accrue, meaning individuals with life expectancy shorter than the lag time to benefit cannot benefit and may only experience harms. Life expectancy estimation should incorporate functional status, comorbidity burden, and physiologic reserve in addition to chronological age, as substantial heterogeneity exists among individuals of the same age. Goals of care discussion should clarify what outcomes matter most to each patient, as some prioritize longevity while others prioritize function, comfort, or avoiding medicalization. Aligning preventive recommendations with individual goals and prognosis produces care that serves patients rather than protocols.

Cancer screening recommendations for older adults require individualization based on life expectancy and prior screening history. Colorectal cancer screening may continue through age seventy-five for those with life expectancy exceeding ten years, with individualized decisions for ages seventy-six through eighty-five and cessation beyond eighty-five or when life expectancy falls below ten years. Breast cancer screening lacks an explicit upper age limit in USPSTF recommendations, which extend through age seventy-four, but should continue only for women with life expectancy exceeding ten years and willingness to undergo treatment for detected cancer. Cervical cancer screening may cease at age sixty-five for women with adequate prior screening showing no high-grade abnormalities. Prostate cancer screening is generally not recommended for men over seventy years of age.

Geriatric-specific preventive services address conditions of particular importance in older populations. Fall risk assessment should occur annually or when falls are reported, with multifactorial intervention for those at elevated risk including exercise programs, medication review, vision correction, and home safety evaluation. Cognitive assessment is not recommended for universal screening in asymptomatic individuals, but evaluation is warranted when patients or families express concern about memory or when functional decline suggests cognitive impairment. Hearing and vision assessment should occur periodically given the high prevalence of sensory impairment and its impact on function and safety. Medication review at each visit addresses polypharmacy, with specific attention to medications that are potentially inappropriate in older adults. Advance directive completion ensures documentation of preferences and surrogate decision-makers before cognitive impairment may limit capacity.

Deprescribing represents a proactive approach to reducing medication burden that is particularly important in older adults facing polypharmacy-related harms. Review of all medications including over-the-counter products and supplements provides foundation for identifying candidates for discontinuation. Assessment questions whether each medication remains indicated, whether the original indication still applies, and whether the potential benefits continue to outweigh risks in the current clinical context. High-risk medications warrant particular scrutiny, including anticholinergic medications that may impair cognition, sedative-hypnotics that increase fall risk, and opioids that carry multiple risks in older adults. Gradual discontinuation with monitoring for withdrawal symptoms or return of the original indication enables safe medication reduction. Patient engagement in deprescribing decisions increases success and reduces anxiety about medication changes.

<image>Panel A: Framework for geriatric prevention decisions showing consideration of life expectancy, lag time to benefit, patient goals, and comorbidity burden in modifying standard recommendations. Panel B: Cancer screening upper age limits showing colonoscopy, mammography, Pap smear, and PSA recommendations with life expectancy considerations for continuation. Panel C: Geriatric-specific prevention targets including fall risk assessment, cognitive evaluation for concerns, sensory assessment, medication review, and advance care planning with recommended frequencies. Panel D: Deprescribing process showing medication review, indication assessment, high-risk medication identification, and gradual discontinuation with monitoring steps.</image>

IX. Documentation and Tracking

Health maintenance tracking systems ensure that patients receive recommended preventive services without relying solely on patient recall or physician memory during episodic visits. The health maintenance record provides structured documentation of screening tests performed, results obtained, and dates when services are next due. Electronic health records typically incorporate health maintenance modules that track multiple preventive services and generate alerts when services are overdue. Paper-based systems may use flow sheets that provide visual representation of screening status. Regardless of format, effective tracking requires consistent documentation of services provided both within and outside the practice, as screening performed by specialists or other facilities may not automatically populate the primary care record.

Electronic health record tools extend health maintenance tracking from individual patient management to population health oversight. Health maintenance alerts prompt clinicians when services are due during clinical encounters, though alert effectiveness depends upon alert design and clinician response patterns. Registry functions enable identification of all patients who are overdue for specific services, supporting systematic outreach rather than opportunistic intervention only when patients present. Care gap reports generate actionable lists of patients requiring services, which may be distributed to care team members for outreach activities. Pre-visit planning queries identify services due for scheduled patients, enabling preparation of necessary orders and materials before the visit and maximizing efficiency during limited encounter time.

Pre-visit planning optimizes preventive care delivery by identifying needs and preparing resources before patients arrive. Chart review occurring days before scheduled visits identifies overdue preventive services, chronic disease monitoring needs, and required documentation updates. Standing order protocols may authorize staff to order screening tests, administer immunizations, or obtain refill authorizations without individual physician orders, extending care capacity. Team huddles on the morning of clinic sessions provide brief opportunity for team members to review the day's schedule, identify complex patients, and allocate tasks. During-visit checklists ensure that identified needs are addressed during the encounter rather than forgotten amid competing demands. Post-visit follow-up confirms that recommended services were completed and schedules outstanding items.

Quality measurement provides accountability for preventive care performance and enables identification of improvement opportunities. Healthcare Effectiveness Data and Information Set measures constitute the dominant quality measurement framework used by health plans, with numerous measures addressing preventive services. Uniform Data System measures apply to federally qualified health centers and include prevention metrics. Merit-based Incentive Payment System incorporates quality measures that affect Medicare payment, creating financial accountability for performance. Common preventive care measures include cervical cancer screening rates, breast cancer screening rates, colorectal cancer screening rates, and immunization rates for specific vaccines. Performance feedback at individual clinician and practice levels identifies opportunities for improvement and tracks progress over time.

<image>Panel A: Sample health maintenance record showing tracking grid for multiple screening tests with dates of prior completion and next due dates across years. Panel B: EHR health maintenance module screenshot showing alert generation, registry query function, and care gap report interface. Panel C: Pre-visit planning workflow showing chart review, standing order implementation, team huddle, during-visit checklist, and post-visit follow-up sequence. Panel D: Quality measure dashboard displaying practice performance on key preventive measures with comparison to benchmarks and trends over time.</image>

X. Shared Decision-Making

Shared decision-making applies when screening decisions involve preference-sensitive tradeoffs where reasonable patients might reach different conclusions based on their values. Clinical scenarios warranting shared decision-making include those with closely balanced benefits and harms where either screening or not screening represents reasonable choice. Evidence uncertainty situations where potential benefits and harms remain poorly quantified require patient involvement in navigating ambiguity. Value-dependent decisions where outcomes differ in kind rather than magnitude, such as trading longevity risk against procedural discomfort or surveillance burden, depend upon individual patient priorities. USPSTF Grade C recommendations specifically indicate that shared decision-making should occur, though the approach applies broadly whenever significant tradeoffs exist.

The shared decision-making process follows structured steps that ensure patients receive necessary information while their values guide ultimate decisions. Explaining options begins with description of available choices including the option of declining screening, ensuring patients understand that decisions exist rather than simply following presumed requirements. Presenting evidence involves communicating benefits in terms of absolute risk reduction rather than relative measures that may exaggerate impact, while also presenting harms including false positive rates, overdiagnosis, and procedure risks. Eliciting values explores what outcomes matter most to the patient and how they weigh competing considerations such as peace of mind versus avoiding unnecessary procedures. Discussion addresses questions and concerns, with clinicians offering their perspective while acknowledging that the ultimate decision belongs to the patient. Documentation records the discussion and decision, providing medicolegal protection and ensuring continuity.

Decision aids support shared decision-making by presenting balanced information in accessible formats that patients can review outside of time-pressured clinical encounters. Printed materials including pamphlets and booklets present screening information at appropriate reading levels with graphics that enhance understanding. Video decision aids may be more engaging and accessible for patients with limited literacy. Interactive online tools enable patients to explore how different value weightings affect recommendations and may include calculators that estimate individual risk. Decision aids should present both benefits and harms in comparable formats, avoid framing effects that bias toward particular choices, and include guidance for incorporating patient values into decisions. Evidence demonstrates that decision aids improve knowledge, reduce decisional conflict, and increase alignment between values and choices without reducing screening uptake for those who would benefit.

Prostate cancer screening exemplifies shared decision-making in practice, illustrating application of these principles to a common clinical scenario. The conversation explains that prostate cancer screening with PSA testing is optional, with potential benefits and harms that depend upon individual circumstances and values. Benefits include possible detection of aggressive cancer at a stage when treatment may be curative, with estimated prevention of one to two prostate cancer deaths per thousand men screened over ten years. Harms include substantial false positive rates requiring biopsy to resolve, detection of indolent cancers that would never have caused symptoms leading to overtreatment with associated risks of incontinence and erectile dysfunction, and anxiety associated with abnormal results and surveillance. Values exploration addresses how the patient weighs the possibility of dying from prostate cancer against treatment side effects, surveillance burden, and uncertainty. The decision should be documented regardless of the outcome, with screening offered to those who choose it and reassurance provided to those who decline.

<image>Panel A: Clinical scenarios for shared decision-making showing balanced benefits and harms, evidence uncertainty, value-dependent decisions, and Grade C recommendations with examples of each. Panel B: Shared decision-making process flowchart showing explain options, present evidence, elicit values, discuss, decide together, and document steps. Panel C: Decision aid components including written materials, video resources, and interactive tools with quality criteria for balanced presentation. Panel D: Prostate cancer screening conversation framework showing benefit presentation, harm disclosure, values exploration, and documentation elements.</image>

Summary

• USPSTF grading ranges from A (strongly recommend) through D (recommend against) and I (insufficient evidence), guiding clinical application of screening recommendations
• Breast cancer screening with mammography is recommended biennially for ages fifty through seventy-four, with individualized decisions for ages forty through forty-nine
• Cervical cancer screening involves Pap smear every three years for ages twenty-one through twenty-nine, with Pap every three years, co-testing every five years, or HPV alone every five years for ages thirty through sixty-five
• Colorectal cancer screening from ages forty-five through seventy-five offers multiple equivalent options including colonoscopy every ten years or annual FIT
• Lung cancer screening with annual low-dose CT targets adults ages fifty through eighty with twenty or more pack-year smoking history who currently smoke or quit within fifteen years
• ASCVD risk calculator guides statin therapy decisions, with high-intensity statins recommended for clinical ASCVD, LDL greater than 190, and high ten-year risk
• Adult immunizations include annual influenza, Tdap once with Td boosters every ten years, zoster vaccine at age fifty, and pneumococcal vaccination at age sixty-five
• Depression screening is recommended for all adults with adequate systems to ensure diagnosis and treatment for positive screens
• Shared decision-making applies to preference-sensitive decisions where reasonable patients might reach different conclusions, including Grade C recommendations
• Quality tracking through health maintenance alerts, registries, and care gap reports enables systematic preventive care delivery

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown